Big Pharma Returning to U.S. Price Hikes In January After Pause

According to Reuters, Novartis and Bayer are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January.

This ends a self-declared halt to increases made by a pharma industry under pressure from the Trump administration.

The hikes will pose a new challenge to President Donald Trump’s pledge to lower the costs of prescription medications in the world’s most expensive pharmaceutical market.

Pfizer said it would defer hikes until January 2019 to support the administration as it pursued its new pricing policies.